Investors
Mauna Kea Technologies
Stock Information
Mauna Kea Technologies
Stock Information
Stay up to date on all our investor news
0,0806€
Last updated
24/05/2025 - 12:32
+0,75%
€10.5M
Sales in 2023
+42%
Sales growth in 2023
excluding exchange rates
+52%
PPU growth in 2023
excluding exchange rates
Events and Presentations
Financial Results
Governance
Mauna Kea Technologies announces the availability of preparatory documents for the Combined General Meeting of June 5, 2025 and the instructions for participation
Voting Rights Information – April 2025
Publication of the 2024 Annual Financial Report
2024 Annual Financial Report (free translation)
Mauna Kea Technologies Reports Full Year 2024 Results and Provides a Business Update
News
Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress
Mauna Kea Technologies announces the availability of preparatory documents for the Combined General Meeting of June 5, 2025 and the instructions for participation
Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week® 2025
Shareholding Structure
A long term vision shared by major strategic shareholders: Johnson & Johnson (NYSE: JNJ) and Telix Pharmaceuticals (ASX : TLX)
Stock Information
STOCK MARKET DATA
Listed on Euronext Growth Paris
Initial listing : July 6, 2011
The number of outstanding shares is : 64,702,127
Industry : healthcare (4000)
Sector : Medical equipment and healthcare services (4530)
IDENTIFICATION CODES
ISIN : FR0010609263
Ticker : ALMKT
ANALYST COVERAGE
Guillaume Cuvillier
Raphaël Génin
STATUTORY AUDITORS
• EY and Others, represented by Mr Franck SEBAG, 1-2 place des Saisons, 92400 Courbevoie- Paris La Défense, France
• Exco Socodec, represented by Monsieur Olivier Gallezot, 51, Avenue Françoise Giroud, Parc Valmy, 21066 Dijon